



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### The immune system's contribution to the clinical efficacy of EGFR antagonist treatment

**Citation for published version:**

MacDonald, F & Zaiss, D 2017, 'The immune system's contribution to the clinical efficacy of EGFR antagonist treatment', *Frontiers in pharmacology*, vol. 8, 575, pp. 1-7.  
<https://doi.org/10.3389/fphar.2017.00575>

**Digital Object Identifier (DOI):**

[10.3389/fphar.2017.00575](https://doi.org/10.3389/fphar.2017.00575)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Frontiers in pharmacology

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



1 **The immune system's contribution to the clinical efficacy of EGFR antagonist treatment**

2

3 Felicity Macdonald and Dietmar M.W. Zaiss\*

4

5 Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, UK.

6

7

8

9

10 \* to whom correspondence should be addressed:

11 [Dietmar.Zaiss@ed.ac.uk](mailto:Dietmar.Zaiss@ed.ac.uk)

12

13

14

15

16

17

18 **Abstract**

19 Epidermal Growth Factor Receptor (EGFR) antagonists were one of the first anti-cancer  
20 treatments developed targeting a Receptor Tyrosine Kinase. However, the underlying mode of  
21 action of how EGFR antagonist application can explain its clinical efficacy in different types of  
22 cancers remains largely unresolved. Numerous findings have suggested that a substantial portion  
23 of the effects attributed to EGFR antagonist treatment might not be based on *direct* influence on  
24 the tumour itself. Instead it may be based on *indirect* effects, potentially mediated via the immune  
25 system. In this review the role of the EGFR for the functioning of the immune system is discussed,  
26 alongside how EGFR antagonist treatment could be impacting tumour growth by blocking  
27 macrophage and FoxP3-expressing regulatory CD4+ T cell function. Based on these findings, we  
28 consider implications for current treatment schemes and suggest novel approaches to improve the  
29 efficacy of EGFR antagonist treatment in the future. Finally, we propose potential ways to improve  
30 EGFR antagonists, in order to enhance their clinical efficacy whilst diminishing unwanted side  
31 effects.

32

33

34

35

1 The Epidermal Growth Factor Receptor (EGFR) was the first Receptor Tyrosine Kinase to be  
2 described (1). Due to the fact that many tumours of epidermal origin express high levels of this cell  
3 surface receptor, antagonists targeting the EGFR were also amongst the first biologicals approved  
4 for the treatment of cancer patients (2). Examples of such antagonists include two EGFR blocking  
5 antibodies, Cetuximab and Panitumumab, as well as two chemical tyrosine kinase inhibitors,  
6 Erlotinib and Gefitinib. Many further antagonists are now in advanced development. These EGFR  
7 antagonists show considerable clinical efficacy and, in particular, their use in colon carcinoma as  
8 well as that in head and neck cancer treatment can substantially extend survival time (2).

9  
10 Fundamentally, the clinical efficacy of EGFR antagonists in cancer treatment was an unexpected  
11 finding, as the EGFR is ubiquitously expressed throughout the human body and not itself an  
12 oncogene. Contrary, deletion of the EGFR specifically in hepatocytes has been shown to lead to  
13 enhanced development of liver cancer in mice (3), demonstrating that this receptor may have  
14 beneficial properties in the protection against cancer. Only a mutated form of the EGFR, known as  
15 EGFRvIII, can cause cancer. This mutation deletes exons 2 to 7 of the EGFR gene, leading to low-  
16 level constitutive signalling that can drive tumour progression (4).

17 A number of different direct modes of action have been suggested that may explain the clinical  
18 efficacy of EGFR antagonist treatment in cancer therapy. One of the original suggestions was that  
19 tumours grow “addicted” to growth factor signalling. As such, interruption of this signalling was  
20 assumed to lead to cancer cell death. However, this suggestion was substantially based around  
21 the fact that many tumours strongly overexpress the EGFR, and it was assumed that such an  
22 extreme overexpression of this receptor would supposedly lead to higher sensitivity of the tumour  
23 cells to growth factor-induced proliferation. Nevertheless, it was soon recognised that tumour-  
24 specific overexpression of the target molecule was not a prognostic marker of tumour treatment  
25 (5)(6), as tumours that did not express detectable levels of the EGFR still reacted to antagonist  
26 treatment such as monoclonal antibody therapy (7). It has also been shown that tumours  
27 responsive to EGFR antagonist treatment *in vivo* are often not sensitive to monoclonal antibody  
28 treatment in cell culture when explanted (8).

29 As alternative modes of action, in particular with antibody-based treatments, complement-mediated  
30 and natural killer (NK) cell-mediated killing of tumour cells has been suggested. However, as the  
31 EGFR is also ubiquitously expressed on healthy tissues, such modes of action would only be able  
32 to explain for the clinical efficacy of treatment on tumour cells that express an elevated level of the  
33 target molecule. Thus, it appears reasonable to assume that the clinical efficacy of EGFR  
34 antagonist treatment may not be based on *direct* effects on the tumour, but may also be in part  
35 based on *indirect* effects. One such possibility may be the interaction of antagonists with EGFR  
36 expression on healthy cells in the tumour microenvironment, such as tumour-intrinsic fibroblasts, or  
37 on cells of the immune system. In support of such an assumption it has been reported that

1 Cetuximab treatment in particular can activate the host anti-tumour immune response (8)(9).  
2 Furthermore, Garrido et al. demonstrated, in a mouse model of lung carcinoma, that the anti-  
3 metastatic effect of EGFR inhibitor treatment crucially depends upon the immune system (10).  
4 Depletion of either CD8+ or CD4+ T cells abrogated the beneficial effects seen following EGFR  
5 inhibitor treatment (10), therefore these findings strongly suggest that the immune system may  
6 substantially contribute to the clinical efficacy of EGFR antagonist treatment.  
7 This review will discuss evidence that implicates the involvement of the immune system in EGFR  
8 antagonist-based tumour treatment, considering the measures required to improve current  
9 treatment in order to enhance clinical efficacy and diminish any associated side effects.

10

### 11 **Role of the EGFR in the immune system**

12 It has been well established that the EGFR is expressed on many different haematopoietic cell  
13 types and that its expression is of central importance for their functioning. These cell types include  
14 macrophages (11)(3), monocytes (12), plasma cells (13) and certain T cell subsets such as  
15 effector CD4 T cells and FoxP3-expressing regulatory CD4 T cells (Tregs) (14). It is therefore  
16 plausible that EGFR antagonists used to target tumours can interfere with the functioning of the  
17 immune system. This potentially explains for the enhanced susceptibility to infections seen in  
18 patients treated with these antagonists (15), and the observed mortality of patients arising from  
19 severe bacterial infections when treated with immunosuppressant mTOR inhibitors in combination  
20 with EGFR inhibitors (15).

21 Tumours require interaction with many different host immune cell populations for their growth and  
22 survival. Mast cells, for instance, are recruited to tumour environments where they mature and  
23 release angiogenic mediators to support the development of new blood vessels and provide  
24 growth factors to support tumour development (16). Tumour associated macrophages (TAM) are  
25 another key immune cell type implicated in tumour growth. TAMs have been found to stimulate  
26 angiogenesis, as well as secreting molecules that enhance tumour cell proliferation and  
27 metastasis, and promoting tumour progression by establishment of a suppressive  
28 microenvironment (17). Additionally, other suppressive cell types are also found in the tumour  
29 microenvironment, including regulatory T cells (Treg) and myeloid-derived suppressor cells  
30 (MDSC). These cells dampen the anti-tumour immune response by interacting with cells such as  
31 NK cells, T cells and dendritic cells (DC) (18)(19). Thus, it is reasonable to assume that EGFR  
32 antagonist interference with any of these leukocytes' function may advantageously contribute to  
33 the clinical efficacy of anti-tumour treatments.

34

### 35 **Role of EGFR expression for macrophage function**

36 Macrophages make up a substantial component of many tumours. Clinical studies have indicated  
37 that cancers containing high infiltrates of macrophages are associated with poor prognosis for the

1 patient (20). Recent studies in a number of different mouse tumour models have revealed that  
2 EGFR-mediated signalling, specifically within macrophages, substantially contributes to the  
3 initiation of tumour growth (3)(21)(22). In line with these findings, the group of John Condeelis  
4 revealed an EGFR based cross-talk between macrophages and tumour cells (23). In a paracrine  
5 loop intra-tumoural macrophages secrete EGF, which binds to the EGFR on tumour cells,  
6 promoting their invasion. At the same time, tumour cells secrete colony-stimulating factor-1 (CSF-  
7 1) which in turn promote the expression of EGF by macrophages (23). Nevertheless, in all of the  
8 mouse tumour models used, EGFR gene-deletion in the cancerous target tissue had no influence  
9 on the development of tumours. However, EGFR gene-deletion in macrophages did influence  
10 tumour development. This suggests a role for macrophage-intrinsic EGFR-mediated signalling in  
11 the establishment of the tumour microenvironment. Mechanistically it has been shown that EGFR  
12 expression regulates macrophage cytokine production (3)(24), and that macrophage-derived  
13 cytokines are predominant drivers of tumourigenesis (3)(21)(22). Thus, by blocking EGFR function  
14 in tumour residential macrophages during EGFR antagonist treatment this supply of cytokines may  
15 be interrupted, leading to diminished tumour growth and tumour-intrinsic instability.

16

### 17 **Role of EGFR expression for regulatory T cell function**

18 One further immune cell population of particular interest in cancer treatment are FoxP3-expressing  
19 regulatory T cells (Tregs). The role of EGFR expression for Treg functioning is also well  
20 established (14) and Tregs play a role in maintaining immune homeostasis by negatively regulating  
21 other immune cell types. Thereby Tregs prevent the development of autoimmunity through  
22 establishment of peripheral tolerance to self-antigens. Tumours are able to exploit the suppressive  
23 nature of Tregs found within the tumour microenvironment, and Tregs have been shown to traffic  
24 to, proliferate and mature within the tumour microenvironment under influence of local factors  
25 produced by tumours and associated cells (18). As such, the presence of Tregs allows tumours to  
26 escape immune surveillance as they dampen anti-tumour immune responses, enabling the  
27 induction of immunological tolerance against tumour-antigens.

28 For optimal functioning, both human and murine Tregs are dependent on EGFR-mediated intrinsic  
29 signalling upon binding of the ligand Amphiregulin (AREG)(14). AREG is known to be a type II  
30 cytokine involved in wound healing and contributes to host resistance to helminth infections  
31 (25)(26). In contrast to most other EGFR ligands, the binding of AREG to the EGFR induces a  
32 prolonged, tonic signal through the MAP-kinase (MAPK) signalling pathway that does not lead to  
33 the internalisation of the receptor. Tregs express the EGFR under inflammatory conditions, as  
34 witnessed by elevated levels of EGFR found on tumour-infiltrating Tregs derived from wild type  
35 (wt) mice with B16 melanomas, as well as EGFR expression on human Tregs with an activated  
36 phenotype of FoxP3<sup>hi</sup> and CD45RA<sup>-</sup> (14). *In vitro* treatment of EGFR-expressing Tregs with AREG

1 enhances their suppressive capacity, shown by decreased proliferation of peripheral blood  
2 mononuclear cells (PBMC) incubated with both Tregs and AREG. The group of Mark Wilson  
3 further demonstrated that the addition of AREG increases the release rate of microRNA-containing  
4 exosomes from Tregs, which these cells use as a means of Treg-mediated immune suppression  
5 (27). In consequence, Tregs that either lacked EGFR expression or were transferred into an  
6 AREG-deficient environment could not suppress the development of autoimmune diseases in both  
7 a dermatitis and a T-cell transfer-based model of colitis (14). This clearly demonstrates that Tregs  
8 are directly dependent on AREG-induced and EGFR-mediated signalling for their *in vivo*  
9 functioning.

10  
11 It is widely accepted that Tregs play a pivotal role in creating the suppressive tumour  
12 microenvironment. Using a well-established murine B16 melanoma immunisation model (28), it  
13 has been demonstrated that AREG plays a critical role in such Treg-mediated tumour immune  
14 suppression (14). In B16 tumours, Tregs protect against immunisation-induced CD8+ T cell-  
15 mediated anti-tumour immune responses. It has been shown that when C57BL/6 wt mice were  
16 transplanted with B16 tumours, and an anti-tumour CD8+ T cell response induced by immunisation  
17 with immunogenic tumour-epitope pulsed bone marrow-derived dendritic cells (BM-DC), large  
18 tumours grew 3 weeks following tumour transfer. In contrast, BM-DC immunised *Areg* gene-  
19 deficient mice and mice lacking EGFR expression specifically on Tregs (*FoxP3-cre* x  
20 *EGFR<sup>fl/fl</sup>*)(unpublished data) efficiently rejected the transplanted tumours upon immunisation (14).  
21 These findings demonstrate that AREG enables Tregs to suppress anti-tumour immune  
22 responses.

23  
24 Remarkably, mast cells have been determined to be the critical source of AREG, enhancing Treg  
25 function (14). It has been shown before that mast cells can cooperate with Tregs to suppress skin  
26 transplant-specific immune responses, a model in which the immunosuppressive function of Tregs  
27 is well established to induce immunological tolerance (29). Furthermore, in a model of T cell  
28 transfer-induced colitis, using a mast cell-deficient mouse strain *c-kit<sup>w-sh/w-sh</sup>* backcrossed onto a  
29 *RAG1<sup>-/-</sup>* background, it was demonstrated that mice reconstituted with *wt* bone marrow-derived  
30 mast cells (BM-MC) prior to co-transfer of naïve CD4+ T cells and Tregs had a much lower colitis  
31 score than mast cell-deficient mice that had either not been reconstituted or reconstituted with  
32 *Areg<sup>-/-</sup>* BM-MC. This clearly demonstrates that mast cell-derived AREG is essential to restore the  
33 suppressive capacity of transferred Tregs (14).

34 In further accordance with these findings, it has also been demonstrated that the efficacy of tumour  
35 immune therapy is enhanced in mast cell deficient mouse strains (30)(14). Mast cells are found to  
36 accumulate at the edge of tumours, and in some tumour types this accumulation has been shown  
37 to correlate with a poor prognosis for cancer patients (31). Tumour-associated Tregs have also

1 been shown to localise on tumour margins, within so-called tertiary lymphoid structures (TLS)(32).  
2 TLSs are often formed at sites of infection, inflammation and cancer, and similarly to secondary  
3 lymphoid structures they contain B cell and T cell zones along with high endothelial venules. This  
4 composition allows for the formation of efficient adaptive immune responses, as TLSs allow entry  
5 of immune cells into the tumour environment and priming of lymphocytes. It is here that Tregs are  
6 believed to suppress anti-tumour immune responses. Reconstitution of mast cell-deficient *c-kit*<sup>w-  
7 sh/w-sh</sup> mice with *wt* BM-MC prior to tumour transfer, and immunisation with tumour-epitope pulsed  
8 BM-DCs, led to enhanced resistance to tumour immune therapy. However, when *c-kit*<sup>w-sh/w-sh</sup> mice  
9 were reconstituted with *Areg*<sup>-/-</sup> BM-MC prior to immunisation, tumour protection against the induced  
10 immune responses was lost. These findings highlight that mast cell-derived AREG increases the  
11 suppression of Tregs *in vivo*, thereby enabling tumour-resident Tregs to suppress anti-tumour  
12 immune responses (Figure 1).

13

14 Taken together, targeted interference with Treg-intrinsic EGFR signalling in human tumours may  
15 as such contribute to the observed efficacy of EGFR antagonists. Consistent with such an  
16 assumption is the fact that the best independent prognostic indicator for the efficacy of treatment in  
17 patients with tumours expressing a non-mutated form of K-Ras, is the expression level of AREG in  
18 the serum of cancer patients (33)(34)(35)(36).

19

## 20 **Role of regulatory T cells in human cancer**

21 In mouse tumour models the importance of Tregs has repeatedly been demonstrated. In contrast,  
22 their importance in established human tumours remains a more controversial and less well studied  
23 subject. An elevated number of FoxP3-expressing CD4<sup>+</sup> T cells have been described within  
24 several solid tumours; including ovarian and non-small-cell lung cancer tumours, and in the  
25 peripheral blood of breast, colorectal, and lung cancer patients (18). Data from patients suffering  
26 from a wide range of cancer types has further indicated that there appears to be a positive  
27 correlation between increased number of intra-tumoural FoxP3-expressing CD4<sup>+</sup> T cells and poor  
28 prognosis for cancer patients (37). Unfortunately, both Tregs and activated human CD4<sup>+</sup> T cells  
29 transiently express the transcription factor FoxP3 (38). Therefore, an exact determination of the T  
30 cell phenotype of human FoxP3-expressing CD4<sup>+</sup> T cells requires the analysis of the methylation  
31 status of the FoxP3 gene locus (39). Such analysis relies upon an assay only rarely performed on  
32 patient biopsy-derived T cells. In addition, the relevance of Tregs may be less important in the  
33 situation of established tumours that have already managed to circumvent and tolerate potential  
34 immune responses. Together this suggests that while Treg function may play a critical role at  
35 specific time points during the establishment of tumours, at the exact point at which the biopsy are  
36 taken Treg function may no longer play an essential role for tumour growth.

1 Nevertheless, clear evidence for the importance of Treg function during tumour immunotherapy  
2 exists. In recent years, the use of anti-CTLA-4 antibodies has gained significant support and  
3 success in the treatment of several types of tumours; supposedly, by reinvigorating tumour-specific  
4 cytotoxic CD8+ T cells suppressed by CTLA-4-expressing Tregs (40). Furthermore, the importance  
5 of Tregs in limiting the efficacy of immunotherapy has been well demonstrated in clinical cancer  
6 therapy. For example, it has been reported that the efficacy of vaccination against a high risk HPV  
7 type (HPV16) in patients with cervical cancer was directly correlated with the frequency of FoxP3-  
8 expressing CD25+ CD4+ T cells in patient peripheral blood following vaccination (41). Also, in  
9 clinical studies in which patients received chemotherapy followed by adoptive immunotherapy, the  
10 level of Treg reconstitution after transfer appeared inversely correlated with patient response to  
11 therapy (42). Thus, it is now assumed that the balance between effector T cells and Tregs may  
12 determine the impact of the anti-tumour therapy.

13 Collectively, these findings strongly suggest that Treg function might also play an important role in  
14 human tumour immune therapy, and we may assume that EGFR antagonist treatment-associated  
15 interference with Treg-mediated immune suppression enhances the efficacy of such cancer  
16 treatments.

17

### 18 **Improved applications of EGFR antagonists**

19 The knowledge that EGFR inhibitor treatment may suppress the function of Tregs, thus aiding in  
20 improving the efficacy of tumour immunotherapy, allows the novel exploration of combination  
21 therapy. By combining current therapies with the use of EGFR antagonists, enhanced anti-tumour  
22 immune responses in cancer patients may be seen (Figure 2).

23 One such therapy includes tumour vaccination, which in the past has often failed in clinical  
24 applications, potentially due to a Treg-mediated immunosuppressive tumour microenvironment. It  
25 has already been demonstrated in a mouse model of B16 melanoma that combined therapy of  
26 tumour immunisation with EGFR antagonist treatment improves the efficacy of either treatment  
27 alone (14). B16 tumours were transferred into *wt* C57BL/6 mice, and the mice later immunised with  
28 either tumour antigen-pulsed BM-DCs or EGFR-blocking nanobodies, BM-DCs in combination with  
29 EGFR-blocking nanobodies, or alone. Mice that were given nanobodies or antigen-pulsed BM-DCs  
30 alone showed little to no regression of tumour growth. However, mice that were immunised with  
31 BM-DCs in combination with nanobody treatment developed significantly smaller tumours;  
32 demonstrating the improved efficacy of combined therapies in this mouse model (14).

33 Another such treatment that could be combined with current EGFR inhibitor therapy is  
34 chemotherapy (CT). CT is currently one of the most common forms of cancer treatment, with the  
35 efficacy of CT depending on the type of cancer and the stage of tumour development. CT has a  
36 variety of effects on the immune system including, of importance, immunosuppression through



1 depletion of immune cells such as dividing T cells. The group of Zitvogel and Kroemer have shown  
2 elegantly that CT can also induce and enhance anti-tumour immune responses in a number of  
3 ways (43). Firstly, CT induces tumour cell death. As such, tumour (neo-) antigens are released and  
4 can subsequently be presented to tumour-specific T cells priming new immune responses against  
5 tumour cells or re-activating a dormant anti-tumour T cell response. In addition, CT-induced tumour  
6 cell death diminishes the overall tumour load temporarily, and thus with it the associated  
7 immunosuppressive microenvironment. However, most importantly for combined immunotherapy,  
8 CT transiently induces lymphopenia. This leads to substantial T cell proliferation that can again  
9 reactivate dormant T cell responses. It has further been well established that in situations of  
10 lymphopenia, the activation of Treg populations plays an important role in dampening such  
11 dormant responses; for instance, to prevent the induction of autoimmune responses (44). The  
12 application of EGFR antagonists, and thus the suppression of Tregs function during this immune  
13 replenishment phase following CT-induced lymphopenia, may have the capacity to substantially  
14 improve the reactivation of anti-tumour immune responses and efficacy of CT (Figure 2). Of  
15 interest, in colon carcinoma patients, EGFR antagonist treatment appears efficient only in  
16 combination with chemotherapy.

17 Another promising line of combined therapy in cancer treatment is the combination of CT with  
18 adoptive cell transfer (ACT). In most cases, ACT describes the isolation of T cells from cancer  
19 patients. These T cells are then further cultured *in vitro*, and subsequently activated and expanded  
20 *ex vivo* with tumour-specific antigens prior to re-infusion. Alternatively, effector T cells are  
21 transduced with tumour-antigen specific TCRs eliciting a stronger anti-tumour immune response  
22 following later retransfer into the patient (45). ACT is normally combined with non-myeloid  
23 depleting CT prior to cell transfer, inducing lymphopenia-associated cell proliferation. One of the  
24 most critical aspects in determining the efficacy of ACT is thereby the rate in which Tregs expand  
25 following CT (42). Patients with a rapid recovery of Treg frequencies in the blood following therapy  
26 were mainly non-responders, while patients who had a delayed Treg recovery were responders  
27 (42). Therefore, it is tempting to speculate that the application of EGFR antagonists in combination  
28 with ACT during CT-induced lymphopenia, and the following recovery phase, could substantially  
29 diminish Treg function during a critical time point of treatment thus substantially improving the  
30 efficacy of such treatment (Figure 2).

31

## 32 **Outlook**

33 Taken together, recent developments suggest a prominent immune involvement in the clinical  
34 efficacy of EGFR antagonist treatments. To fully verify such an involvement, it appears warranted  
35 that further and more focused analysis of tumour material - derived from cancer patients treated  
36 with EGFR antagonists - should be performed. These studies should address EGFR expression  
37 levels of intra-tumoural Treg populations during different stages of tumour development, and

1 determine whether a shift in effector T cell to Treg ratio occurs in patients that undergo treatment  
2 with EGFR antagonists. Nevertheless, this newfound appreciation of the link between EGFR  
3 inhibitors and the immune system provides novel insights into how EGFR antagonists may function  
4 during cancer treatment, permitting adjustments to our current use of these drugs in the clinic. As  
5 the EGFR is expressed on a wide variety of cells, and is important for tissue homeostasis, off-  
6 target side effects of current EGFR inhibitors used in cancer treatment are common and can often  
7 be severe. To diminish such side effects, methods are required to be developed which can target  
8 EGFR antagonists specifically to tumour-residential Treg populations. As such, much lower  
9 concentrations of drugs would be needed as their effects would remain restricted to Tregs; thus  
10 enhancing the efficacy of treatment whilst diminishing side effects associated with EGFR  
11 antagonist treatment.

12

13

1 **References:**


- 2 1. Gschwind A, Fischer OM, Ullrich A. Timeline: The discovery of receptor tyrosine kinases:  
3 targets for cancer therapy. *Nat Rev Cancer*. 2004 May;4(5):361–70.
- 4 2. Ciardiello F, Tortora G. EGFR Antagonists in Cancer Treatment. *N Engl J Med*. 2008 Mar  
5 13;358(11):1160–74.
- 6 3. Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, et al. EGFR has a tumour-  
7 promoting role in liver macrophages during hepatocellular carcinoma formation. *Nat Cell Biol*.  
8 2014 Oct;16(10):972–81.
- 9 4. Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII):  
10 where wild things are altered. *FEBS J*. 2013 Nov;280(21):5350–70.
- 11 5. Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A. Emerging perspectives in epidermal  
12 growth factor receptor targeting in head and neck cancer. *Head Neck*. 2008 May;30(5):667–74.
- 13 6. Burtneß B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III Randomized Trial of  
14 Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head  
15 and Neck Cancer: An Eastern Cooperative Oncology Group Study. *J Clin Oncol*. 2005 Dec  
16 1;23(34):8646–54.
- 17 7. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab Shows Activity  
18 in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor  
19 Receptor by Immunohistochemistry. *J Clin Oncol*. 2005 Mar 20;23(9):1803–10.
- 20 8. López-Albaitero A, Ferris RL. Immune Activation by Epidermal Growth Factor Receptor–  
21 Specific Monoclonal Antibody Therapy for Head and Neck Cancer. *Arch Otolaryngol Neck  
22 Surg*. 2007 Dec 1;133(12):1277–81.
- 23 9. Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y, Fu Y-X. Cetuximab-mediated  
24 Tumor Regression Depends on Innate and Adaptive Immune Responses. *Mol Ther*. 2013  
25 Jan;21(1):91–100.
- 26 10. Garrido G, Lorenzano P, Sánchez B, Beausoleil I, Alonso DF, Pérez R, et al. T cells are crucial  
27 for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. *Cancer  
28 Immunol Immunother*. 2007 Nov 1;56(11):1701–10.
- 29 11. Scholes AGM. Overexpression of Epidermal Growth Factor Receptor Restricted to  
30 Macrophages in Uveal Melanoma. *Arch Ophthalmol*. 2001 Mar 1;119(3):373.
- 31 12. Chan G, Nogalski MT, Yurochko AD. Activation of EGFR on monocytes is required for human  
32 cytomegalovirus entry and mediates cellular motility. *Proc Natl Acad Sci*. 2009 Dec  
33 29;106(52):22369–74.
- 34 13. Mahtouk K, Hose D, Rème T, De Vos J, Jourdan M, Moreaux J, et al. Expression of EGF-  
35 family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for  
36 myeloma cells. *Oncogene*. 2005 Feb 28;24(21):3512–24.
- 37 14. Zaiss DMW, van Loosdregt J, Gorlani A, Bekker CPJ, Gröne A, Sibilía M, et al. Amphiregulin  
38 Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor.  
39 *Immunity*. 2013 Feb 21;38(2):275–84.

- 1 15. Burtneß B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ. Comment on “Epidermal  
2 Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling.” *Sci Signal*. 2012 Dec  
3 11;5(254):lc5-lc5.
- 4 16. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: Angiogenesis, tissue  
5 remodelling and immune-modulation. *Biochim Biophys Acta BBA - Rev Cancer*. 2009 Aug  
6 1;1796(1):19–26.
- 7 17. Liu Y, Cao X. The origin and function of tumor-associated macrophages. *Cell Mol Immunol*.  
8 2015 Jan;12(1):1–4.
- 9 18. Zou W. Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol*. 2006  
10 Apr;6(4):295–307.
- 11 19. Ostrand-Rosenberg S, Sinha P. Myeloid-Derived Suppressor Cells: Linking Inflammation and  
12 Cancer. *J Immunol*. 2009 Apr 15;182(8):4499–506.
- 13 20. Zhang Q, Liu L, Gong C, Shi H, Zeng Y, Wang X, et al. Prognostic Significance of Tumor-  
14 Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature. *PLOS ONE*. 2012  
15 Dec 28;7(12):e50946.
- 16 21. Srivatsa S, Paul MC, Cardone C, Holcmann M, Amberg N, Pathria P, et al. EGFR in Tumor-  
17 Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates  
18 With Outcomes of Patients. *Gastroenterology*. 2017 Apr 9;
- 19 22. Hardbower DM, Coburn LA, Asim M, Singh K, Sierra JC, Barry DP, et al. EGFR-mediated  
20 macrophage activation promotes colitis-associated tumorigenesis. *Oncogene* [Internet]. 2017  
21 Mar 6 [cited 2017 Jun 23]; Available from:  
22 [http://www.nature.com/onc/journal/vaop/ncurrent/full/onc201723a.html?WT.feed\\_name=subjects\\_](http://www.nature.com/onc/journal/vaop/ncurrent/full/onc201723a.html?WT.feed_name=subjects_immunology)  
23 [immunology](http://www.nature.com/onc/journal/vaop/ncurrent/full/onc201723a.html?WT.feed_name=subjects_immunology)
- 24 23. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, et al. A paracrine loop between  
25 tumor cells and macrophages is required for tumor cell migration in mammary tumors. *Cancer*  
26 *Res*. 2004 Oct 1; 64(19):7022-9.
- 27 24. Hardbower DM, Singh K, Asim M, Verriere TG, Olivares-Villagomez D, Barry DP, et al. EGFR  
28 regulates macrophage activation and function in bacterial infection. *J Clin Invest*. 2016 Aug  
29 2;126(9):3296–312.
- 30 25. Zaiss DW, Gause W, Osborne L, Artis D. Emerging Functions of Amphiregulin in Orchestrating  
31 Immunity, Inflammation, and Tissue Repair. *Immunity*. 2015 Feb;42(2):216–26.
- 32 26. Zaiss DM, Yang L, Shah PR, Kobie JJ, Urban JF, Mosmann TR. Amphiregulin, a TH2 Cytokine  
33 Enhancing Resistance to Nematodes. *Science*. 2006 Dec 15;314(5806):1746–1746.
- 34 27. Okoye IS, Coomes SM, Pelly VS, Czieso S, Papayannopoulos V, Tolmachova T, et al.  
35 MicroRNA-Containing T-Regulatory-Cell-Derived Exosomes Suppress Pathogenic T Helper 1  
36 Cells. *Immunity*. 2014 Jul;41(1):89–103.
- 37 28. Suttmüller RPM, Duivenvoorde LM van, Elsas A van, Schumacher TNM, Wildenberg ME,  
38 Allison JP, et al. Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and  
39 Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for  
40 Suppression of Autoreactive Cytotoxic T Lymphocyte Responses. *J Exp Med*. 2001 Sep  
41 17;194(6):823–32.

- 1 29. Lu L-F, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, et al. Mast cells are  
2 essential intermediaries in regulatory T-cell tolerance. *Nature*. 2006 Aug 31;442(7106):997–  
3 1002.
- 4 30. Wasiuk A, Dalton DK, Schpero WL, Stan RV, Conejo-Garcia JR, Noelle RJ. Mast cells impair  
5 the development of protective anti-tumor immunity. *Cancer Immunol Immunother*. 2012  
6 Dec;61(12):2273–82.
- 7 31. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor  
8 prognosis in pulmonary adenocarcinoma. *Cancer*. 2000 Jun 15;88(12):2686–92.
- 9 32. Joshi N, Akama-Garren E, Lu Y, Lee D-Y, Chang G, Li A, et al. Regulatory T Cells in Tumor-  
10 Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. *Immunity*.  
11 2015 Sep;43(3):579–90.
- 12 33. Tinhofer I, Klinghammer K, Weichert W, Knodler M, Stenzinger A, Gauler T, et al. Expression  
13 of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of  
14 the Head and Neck Receiving Cetuximab-Docetaxel Treatment. *Clin Cancer Res*. 2011 Aug  
15 1;17(15):5197–204.
- 16 34. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al.  
17 Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in  
18 Metastatic Colorectal Cancer Treated With Cetuximab. *J Clin Oncol*. 2009 Oct  
19 20;27(30):5068–74.
- 20 35. Ford SK, Garrett C, Clark E, Basik M, Harbison C, Wong T, et al. **Expression of epiregulin  
21 and amphiregulin and K-RAS mutation status predict disease control in metastatic  
22 colorectal cancer patients treated with cetuximab (Erbix<sup>®</sup>)**. *Cancer Res*. 2007 May  
23 1;67(9 Supplement):5670–5670.
- 24 36. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, et al. Increases of  
25 Amphiregulin and Transforming Growth Factor- $\alpha$  in Serum as Predictors of Poor Response to  
26 Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers. *Cancer Res*. 2005 Oct  
27 15;65(20):9176–84.
- 28 37. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of  
29 regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.  
30 *Nat Med*. 2004 Sep;10(9):942–9.
- 31 38. Wang J, Ioan-Facsinay A, van der Voort EIH, Huizinga TWJ, Toes REM. Transient expression  
32 of FOXP3 in human activated nonregulatory CD4+ T cells. *Eur J Immunol*. 2007 Jan  
33 1;37(1):129–38.
- 34 39. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, et al. Epigenetic Control of the  
35 foxp3 Locus in Regulatory T Cells. *PLOS Biol*. 2007 Jan 30;5(2):e38.
- 36 40. Wolchok JD, Saenger Y. The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation  
37 of T-Cell Activation. *The Oncologist*. 2008 Oct 1;13(Supplement 4):2–9.
- 38 41. Welters MJP, Kenter GG, Steenwijk PJ de V van, Löwik MJG, Meer DMAB der, Essahsah F, et  
39 al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics  
40 and phenotype of induced T-cell responses. *Proc Natl Acad Sci*. 2010 Jun 29;107(26):11895–  
41 9.


- 1 42. Yao X, Ahmadzadeh M, Lu Y-C, Liewehr DJ, Dudley ME, Liu F, et al. Levels of peripheral  
2 CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive  
3 immunotherapy of human cancer. *Blood*. 2012 Jun 14;119(24):5688–96.
- 4 43. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer  
5 chemotherapy. *Nat Rev Immunol*. 2008 Jan;8(1):59–73.
- 6 44. Guerau-de-Arellano M, Martinic M, Benoist C, Mathis D. Neonatal tolerance revisited: a  
7 perinatal window for Aire control of autoimmunity. *J Exp Med*. 2009 Jun 8;206(6):1245–52.
- 8 45. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. *Sci*  
9 *Transl Med*. 2015 Mar 25;7(280):280ps7.

10



**Figure 1: Mast cell-derived Amphiregulin enables tumour-residential regulatory T cells to suppress anti-tumour immune responses**

Tumour-associated Tregs (blue) have been found to localise on tumour margins, along with mast cells (green). **1)** Mast cells cooperate with Tregs, and aid in tumour growth, through secretion of the EGFR-ligand AREG (dark green). **2)** AREG binds to EGFR on Tregs, inducing intrinsic signalling which ultimately enhances Treg suppressive function. **3)** Tregs, with enhanced EGFR-mediated suppressive abilities, can now suppress the action of anti-tumour T cells, and thus aid in tumour immune evasion.



**Figure 2: Direct and indirect effects of tumour immunotherapy**

**1)** For a subset of EGFR+ tumours, growth will be dependent on signals transmitted via the EGFR; therefore blocking this signal with EGFR antagonists could induce tumour cell death by lack of growth signals. **2)** EGFR antagonists, such as monoclonal antibodies, can activate natural killer cell-mediated antibody-dependent cell death (ADCC) on EGFR-expressing cells, such as tumour cells and other immune cell populations in the microenvironment, thus ultimately leading to tumour cell death. **3)** Chemotherapy is a common form of cancer treatment, which has a variety of effects such as tumour cell death and lymphopenia, which re-invigorates the anti-tumour T cell response. **4)** Tumour cell death leads to the release of antigens, which can be presented by antigen presenting cells such as dendritic cells (purple) to prime or re-activate anti-tumour T cells (red). **5)** Anti-tumour T cells can also be indirectly induced or directly transfused via vaccines or adoptive cell therapy respectively, which then can kill tumour cells. **6)** These immune responses can be blocked by tumour-residential regulatory T cells (blue); however, **7)** EGFR antagonists can hinder the suppression of Tregs that is induced via EGFR signalling, thus in turn aiding in tumour immunotherapy, as these Tregs no longer suppress anti-tumour T cells as efficiently.